Evidence map›Paper›PMID 41399277›Full record

ArticleCell transplantation

Do all roads lead to Rome? The heterogeneity of relapsed/refractory diffuse large B-cell lymphoma patients who achieved therapies response and received autologous stem cell transplantation in the era of new targeted drugs.

Jiangtao Li, Wenxuan Huo, Yang Yang, Chunli Zhang, Fengrong Wang, Shengye Lu, Ru Feng, Yang Liu, Leqing Cao, Gaoxiang Wang and 4 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jiangtao LiDepartment of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Wenxuan HuoBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China.ORCID 0009-0006-1392-2081
Yang YangDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Chunli ZhangDepartment of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Fengrong WangBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China.
Shengye LuBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China.
Ru FengDepartment of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Yang LiuBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China.
Leqing CaoBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China.
Gaoxiang WangDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Hui LiuDepartment of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Jihao ZhouDepartment of hematology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, China.
Yang CaoDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xiaodong MoBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this multicenter study, we aimed to identify the prognostic factors for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients who received autologous stem cell transplantation (ASCT) in the era of novel agents and chimeric antigen receptor (CAR) T-cell therapy. A total of 82 relapsed/refractory DLBCL patients receiving ASCT across four transplant centers were enrolled. The 3-year probabilities of disease progression, non-relapse mortality (NRM), progression-free survival (PFS), and overall survival (OS) were 23.5%, 2.8%, 73.7%, and 91.4%, respectively. Patients who received Pola-R-CHP before ASCT had a higher disease progression rate (85.7%

Indexed as

Hematopoietic Stem Cell TransplantationLymphoma, Large B-Cell, DiffuseAdultAgedFemaleHumansMaleMiddle AgedRecurrenceTransplantation, Autologousautologous stem cell transplantationchimeric antigen receptor T-cell therapydiffuse large B-cell lymphomanew targeted drugsrelapsed/refractory DLBCL

Identifiers

PMID41399277
PMCPMC12708990

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.